cas 5580-80-3|| where to buy 2,3,4,5-Tetrafluoroaniline

Nombre del producto:2,3,4,5-Tetrafluoroaniline

IUPAC Name:2,3,4,5-tetrafluoroaniline

Unidad de embalaje	Stock disponible	Precio($)
CM118575-10g	in stock	Ȭư
CM118575-25g	in stock	Ⱥƀǜ
CM118575-100g	in stock	ǊȬǜ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 5580-80-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :5580-80-3; Fórmula molecular:C6H3F4N; Punto de fusión:-; Código de sonrisas:NC1=CC(F)=C(F)C(F)=C1F; Densidad:

: Número de catálogo:CM118575; Peso molecular:165.09; Punto de ebullición:191°C at 760 mmHg; Nº Mdl:MFCD00025153; Almacenamiento:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Glecirasib; On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.